ClariVest Asset Management LLC Takes $1.09 Million Position in GoodRx Holdings, Inc. (NASDAQ:GDRX)

ClariVest Asset Management LLC acquired a new position in shares of GoodRx Holdings, Inc. (NASDAQ:GDRX) in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 153,625 shares of the company’s stock, valued at approximately $1,091,000.

Several other institutional investors also recently modified their holdings of GDRX. Quantbot Technologies LP increased its holdings in shares of GoodRx by 175.2% in the 1st quarter. Quantbot Technologies LP now owns 84,148 shares of the company’s stock worth $597,000 after buying an additional 53,574 shares during the last quarter. GSA Capital Partners LLP bought a new position in GoodRx in the first quarter valued at $1,638,000. Mckinley Capital Management LLC bought a new stake in GoodRx during the first quarter worth about $1,280,000. Mirae Asset Global Investments Co. Ltd. boosted its holdings in shares of GoodRx by 61.1% in the 1st quarter. Mirae Asset Global Investments Co. Ltd. now owns 181,512 shares of the company’s stock worth $1,289,000 after purchasing an additional 68,835 shares in the last quarter. Finally, Schnieders Capital Management LLC bought a new position in shares of GoodRx during the 1st quarter valued at about $93,000. 63.77% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Several analysts have issued reports on GDRX shares. Royal Bank of Canada raised GoodRx from a “sector perform” rating to an “outperform” rating and upped their target price for the stock from $8.00 to $10.00 in a research note on Thursday, May 23rd. TD Cowen increased their target price on shares of GoodRx from $14.00 to $16.00 and gave the company a “buy” rating in a report on Thursday, May 16th. Barclays boosted their price target on shares of GoodRx from $9.00 to $10.00 and gave the stock an “overweight” rating in a research note on Monday, May 20th. Wells Fargo & Company upgraded GoodRx from an “equal weight” rating to an “overweight” rating and lifted their price objective for the stock from $7.50 to $10.00 in a report on Monday, March 25th. Finally, Raymond James upgraded GoodRx from a “market perform” rating to an “outperform” rating and set a $10.00 target price for the company in a report on Thursday, May 16th. One research analyst has rated the stock with a sell rating, seven have given a hold rating and twelve have issued a buy rating to the company’s stock. According to data from MarketBeat.com, GoodRx has an average rating of “Moderate Buy” and a consensus price target of $9.32.

GoodRx Trading Down 4.0 %

NASDAQ GDRX traded down $0.32 during trading on Friday, hitting $7.71. The company had a trading volume of 1,746,946 shares, compared to its average volume of 897,361. The company’s fifty day moving average is $7.78 and its 200-day moving average is $7.07. GoodRx Holdings, Inc. has a one year low of $4.14 and a one year high of $9.37. The company has a quick ratio of 6.29, a current ratio of 6.29 and a debt-to-equity ratio of 1.02.

GoodRx (NASDAQ:GDRX) last issued its quarterly earnings data on Thursday, May 9th. The company reported $0.03 EPS for the quarter, missing the consensus estimate of $0.04 by ($0.01). GoodRx had a positive return on equity of 3.45% and a negative net margin of 0.86%. The company had revenue of $197.88 million during the quarter, compared to analysts’ expectations of $196.20 million. Equities research analysts expect that GoodRx Holdings, Inc. will post 0.17 earnings per share for the current year.

GoodRx Company Profile

GoodRx Holdings, Inc, together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices.